PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review

被引:172
作者
Planes-Laine, Gabrielle [1 ]
Rochigneux, Philippe [1 ,2 ]
Bertucci, Francois [1 ,3 ]
Chretien, Anne-Sophie [2 ]
Viens, Patrice [1 ]
Sabatier, Renaud [1 ,3 ]
Goncalves, Anthony [1 ,3 ]
机构
[1] Aix Marseille Univ, Inserm U1068, CNRS UMR7258, Dept Med Oncol,Inst Paoli Calmettes, F-13009 Marseille, France
[2] Aix Marseille Univ, Inserm U1068, CNRS UMR7258, CRCM Tumor Immunol Lab,Inst Paoli Calmettes, F-13009 Marseille, France
[3] Aix Marseille Univ, Inserm U1068, CNRS UMR7258, CRCM Predict Oncol Lab,Inst Paoli Calmettes, F-13009 Marseille, France
关键词
breast cancer; immunotherapy; PD1; PDL1; triple-negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; T-CELLS; PHASE-II; ANTI-PD-L1; ANTIBODY; PD-L1; EXPRESSION; PROGNOSTIC VALUE; PLUS; PEMBROLIZUMAB; COMBINATION; THERAPY;
D O I
10.3390/cancers11071033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few years, anti-PD1/PD-L1 (Programmed death-ligand 1) agents have been evaluated in breast cancer, particularly in the triple negative subtype, with promising results observed when delivered as monotherapy or in combination with conventional treatments. In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer. In addition, we will discuss the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents.
引用
收藏
页数:25
相关论文
共 117 条
[1]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2]   Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].
Adams, Sylvia ;
Diamond, Jennifer R. ;
Hamilton, Erika ;
Pohlmann, Paula R. ;
Tolaney, Sara M. ;
Chang, Ching-Wei ;
Zhang, Wei ;
Iizuka, Koho ;
Foster, Paul G. ;
Molinero, Luciana ;
Funke, Roel ;
Powderly, John .
JAMA ONCOLOGY, 2019, 5 (03) :334-342
[3]   Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].
Ahmadzadeh, Mojgan ;
Johnson, Laura A. ;
Heemskerk, Bianca ;
Wunderlich, John R. ;
Dudley, Mark E. ;
White, Donald E. ;
Rosenberg, Steven A. .
BLOOD, 2009, 114 (08) :1537-1544
[4]   Breast cancer immunotherapy using magnetised oncolytic viruses [J].
AL-Janabi, H. ;
Conner, J. ;
Taher, Z. ;
Staniland, S. ;
Muthana, M. .
EUROPEAN JOURNAL OF CANCER, 2018, 92 :S4-S4
[5]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[6]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[7]  
[Anonymous], 2014, P T, V39, P213
[8]  
[Anonymous], CANCER RES S
[9]  
[Anonymous], 2018, CANCER RES, DOI DOI 10.1158/1538-7445.SABCS17-P5-21-01
[10]  
[Anonymous], ARR DEV CDK4 6 INH R